



Michigan Quality Improvement Consortium Clinical Practice Guideline Update Alert

Guideline: [Diagnosis and Management of Chronic Kidney Disease](#)

Released: October 2022

This alert provides a summary of only the recommendations which were updated. Refer to the complete guideline for all recommendations and level of evidence.

Updated recommendations include:

All adults at increased risk for CKD

- **Screening** Added: CKD-EPI Creatinine Equation (2021)
- **Testing for diagnosis and staging** Added: 'unexpected' eGFR <30

Adults with CKD

- **Core Principles of Treatment**
 - Added: Minimize iodinated contrast exposure (consider alternative measure if possible but not a complete avoidance necessary).
 - Updated: Vaccines- edited for brevity and add COVID
 - Added: SGLT2 inhibitors to "Cardiovascular risk modification..."
 - Added: Consider assessment for and management of frailty as indicated.
- **Clinical Plan based on CKD Category**
 - Added eGFR levels and degrees of ACR:
 - **eGFR** (G1-G5) and **ACR** (A1 <30 mg/g, A2 30-300 mg/g, A3 >300mg/g)
 - Re-organization and edits for all Stages

Updated Reference

Chronic Kidney Disease Assessment and Management NICE guideline:
<https://www.nice.org.uk/guidance/ng203> (published August 25, 2021)